Changeflow GovPing Healthcare & Life Sciences Dexmedetomidine, Myocardial Protection, Zhejian...
Routine Notice Added Final

Dexmedetomidine, Myocardial Protection, Zhejiang, Phase 4

Favicon for clinicaltrials.gov ClinicalTrials.gov - Phase 4 Trials
Detected
Email

Summary

A Phase 4 clinical trial investigating dexmedetomidine for myocardial protection has been registered on ClinicalTrials.gov under NCT07549282. The trial is being conducted in Zhejiang, China, and is categorised under the drug dexmedetomidine hydrochloride. ClinicalTrials.gov serves as the clinical trial registration database for the National Library of Medicine, operating under NIH authority.

Published by NIH on clinicaltrials.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors ClinicalTrials.gov - Phase 4 Trials for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 10 changes logged to date.

What changed

This document records the registration of a Phase 4 clinical trial on ClinicalTrials.gov, a publicly accessible database maintained by the National Library of Medicine at the NIH. The trial (NCT07549282) studies dexmedetomidine in the context of myocardial protection and is being conducted at a site in Zhejiang, China.

For compliance and regulatory affairs professionals, this entry reflects standard clinical trial disclosure obligations under applicable regulatory frameworks. Principal investigators and trial sponsors should ensure their registrations are current and consistent with any reporting requirements in the relevant jurisdiction of trial conduct.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Show glossary

Get daily alerts for ClinicalTrials.gov - Phase 4 Trials

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 6211 Healthcare Providers
Activity scope
Clinical trial registration Drug development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Healthcare Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov - Phase 4 Trials publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!